› Forums › General Melanoma Community › Virginia/ UVA
- This topic has 4 replies, 2 voices, and was last updated 7 years, 11 months ago by
Shannon B.
- Post
- Replies
-
-
- June 1, 2017 at 1:40 am
Shannon,
I was treated at UVA from Aug 13 to Aug 15 in a Ipi/Nivo sequential trial. Was very pleased with my care there. Dr. Slingluff is probably one of the most known researchers there. He has a pretty strong reputation in the melanoma community from his vaccine research. I was first seen by Dr. Weiss but he retired about half way through my trial and I was switched over to Dr. Elizabeth Gaughan. She is young but very bright. The other melanoma specialist on staff is Dr. Grosh. I never saw him but have a friend who thought the world of him. Overall I think it's a great place. They aren't going to have as many trials as some of your upper tier research centers but the care there is very solid. Let me know if you have any other questions or feel free to PM me.
Brian
-
- June 1, 2017 at 2:01 am
Hi Brian,
My husband was treated in 2006 with a lymph node dissection. Unknown primary. Dr. Levine, head and neck surgeon did the procedure and then referred us to Dr. Slingluff. We opted not to do adjuvant therapy since the only options were interferon, IL2 or a trial. Saw him for follow ups until last year and since it was the 10 year mark they let us go. Well, it's back. They did his scans today and we see Dr. Gaughan tomorrow.
Shannon
-
- June 1, 2017 at 2:31 am
So sorry Shannon. Not sure if you've kept up with the progress made in the last 10 years but there are so many more options now. There is so much more reason to be hopeful nowadays.
Dr. Gaughan is pretty sharp and has a really good bedside manner. She won't steer you wrong. Please let us know what she says. Keytruda or Opdivo would definitely be a viable option but I'd want to know what trials they are running now. I'm pretty sure they have a Keytruda combo with one of Slingluff's vaccines that sounded interesting to me.
Brian
-
- You must be logged in to reply to this topic.